Uncover key drivers, emerging technologies, and competitive movements shaping the antivirals market from 2026–2035 with trusted insights from The Business Research Company
What is the estimated market size of the Antivirals Market by the end of 2030?
The antivirals market size has exhibited robust growth in recent years. It is forecast to increase from $114.4 billion in 2025 to $122.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.7%. Historically, this growth can be attributed to factors such as global viral outbreaks, the burden of hiv and hepatitis, government antiviral stockpiling, the availability of generics, and the expansion of infectious disease programs.
The antivirals market is anticipated to experience robust expansion over the coming years. This market is projected to reach a size of $163.33 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.5%. The expansion during this projected timeframe can be attributed to factors such as emerging viral threats, increased investment in antiviral research and development, greater integration of vaccination and treatment, global health initiatives, and a growing demand for rapid-response therapeutics. Noteworthy trends identified for the upcoming period include an escalating demand for broad-spectrum antivirals, a heightened focus on pandemic preparedness, the wider availability of generic antiviral drugs, increased application in chronic viral infections, and the creation of antivirals with novel mechanisms.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2437&type=smp
What Drivers Are Shaping Future Opportunities In The Antivirals Market?
The growing occurrence of influenza is expected to drive the expansion of the antiviral market in the future. Influenza, commonly known as the flu, represents a highly transmissible viral respiratory illness initiated by influenza viruses, impacting the nasal passages, throat, and lungs. The increased frequency of influenza is largely attributed to cooler temperatures and indoor gatherings, conditions that enable the virus to persist longer and ease its transmission between individuals in close proximity. Antivirals serve as a treatment for influenza, formulated to hinder the proliferation and dispersion of influenza viruses inside the body. For instance, in November 2024, data from the Centers for Disease Control and Prevention, a national public health agency in the US, indicated that the 2023 to 2024 influenza season was linked to approximately 40 million illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths. Consequently, the rising incidence of influenza is propelling the growth of the antiviral market.
Which Segment Groups Are Influencing The Antivirals Market?
The antivirals market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes
3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications
Subsegments:
1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)
2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals
What Trends Are Driving The Growth Trajectory Of The Antivirals Market?
Leading pharmaceutical companies in the antiviral market are prioritizing the creation of novel therapies, notably oral antiviral treatments, to boost patient adherence, broaden access, lower medical expenses, and offer more convenient and potent solutions for viral disease management. Oral antiviral treatments are medicines administered orally for viral infections, functioning by impeding viral multiplication or dissemination within the body, thereby diminishing the infection’s intensity and duration. As an illustration, in May 2023, the US-based pharmaceutical firm Pfizer received approval from the Food and Drug Administration, a US-based government agency, for Paxlovid, making it the initial oral antiviral treatment for COVID-19 in adults. This landmark approval is crucial as it introduces a fresh treatment pathway for COVID-19, particularly as the pandemic evolves into an endemic state. Paxlovid is prescribed for adults experiencing mild-to-moderate COVID-19 who face a high probability of developing severe illness, including the need for hospitalization or a fatal outcome.
Key players in the antiviral market are concentrating on producing sophisticated therapeutic options, including antiviral treatments, to improve patient results and curb viral spread. Antiviral treatments play a vital role in managing viral infections and averting complications in infected individuals. For example, in August 2024, the US-based pharmaceutical company Red Queen’s Technology introduced a range of versatile antivirals. Apple Tree Partners invested $55 million into Red Queen Therapeutics, a biotechnology company focused on developing broad-spectrum antiviral treatments. This company aims to combat infectious agents like COVID-19 and influenza, having successfully advanced a COVID antiviral to Phase 1 trials and secured U.S. government funding for a universal influenza medication. Red Queen, co-founded by Harvard professor Loren Walensky, utilizes stapled lipopeptides to obstruct viral fusion and prevent viruses from entering cells.
Who Are The Core Companies Influencing Trends In The Antivirals Market?
Major companies operating in the antivirals market are AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., AVI Biopharma International Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report
Which Regions Are Projected To Dominate The Antivirals Market In The Coming Years?
North America was the largest region in the anti-viral drug therapy market in 2025. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Antivirals Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=2437&type=smp
Browse Through More Reports Similar to the Global Antivirals Market 2026, By The Business Research Company
Antivirals Market Report 2026
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report
Antiviral Combination Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report
Anti Infective Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model